Keyphrases
Population Pharmacokinetics
71%
Tenofovir
38%
Population Pharmacokinetic Model
32%
Pre-exposure Prophylaxis (PrEP)
30%
Serodiscordant Couples
18%
Physiologically-based Pharmacokinetic Model
16%
Drug Interactions
16%
Transdermal Delivery
16%
Pharmacokinetics
15%
Levonorgestrel
14%
AIDS/HIV
14%
Model-based Analysis
14%
Pharmacokinetic Parameters
14%
Plasma Concentration
13%
Drug Development
13%
Hairless Rat
13%
Adherence Pattern
13%
NONMEM
12%
Volume of Distribution
12%
Pharmacokinetic Simulation
12%
Cisgender
11%
Creatinine Clearance
11%
Model-driven Development
11%
Emtricitabine
11%
Healthy Women
10%
Final Model
10%
Hormonal Contraception
10%
Modeling Approach
10%
Tenofovir Diphosphate
10%
Dosing Information
9%
Parameter Estimation
9%
Non-adherence
9%
Covariate Modelling
8%
Pharmacometrics
8%
Dermal Absorption
8%
Tenofovir Disoproxil Fumarate
8%
Mixed-effects Model
8%
Iontophoretic Patch
8%
Markov
8%
Markov Model
8%
East Africa
8%
Clinical Trials
7%
Dose Report
7%
Dermal Irritation
7%
Sertaconazole Nitrate
7%
Absorption Potential
7%
Continuous Venovenous Hemodiafiltration (CVVHDF)
7%
Silicon Microneedles
7%
Hybrid Genetic Algorithm
7%
Single-objective
7%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Tenofovir
45%
HIV
37%
Clinical Trial
18%
Drug-Drug Interaction
16%
Physiologically Based Pharmacokinetic Modelling
15%
Emtricitabine
15%
Transdermal Delivery
14%
Skin Irritation
14%
Levonorgestrel
14%
Volume of Distribution
14%
Pharmacokinetic Parameter
13%
Drug Development
13%
Creatinine
12%
Hairless Rat
12%
Pharmacokinetic Modeling
11%
Elimination
11%
NONMEM
10%
Contraceptive Agent
10%
Pharmacodynamics
9%
Clinical Study
9%
Tenofovir Disoproxil
9%
Pharmacometrics
8%
Pharmacoeconomics
7%
Sertaconazole
7%
Diclofenac
7%
Digoxin
7%
Amlodipine
7%
Pemetrexed
7%
Hemodialysis
7%
Salcatonin
7%
Granisetron
7%
Hormone Cancer Therapy
7%
Simvastatin
7%
Methotrexate
7%
Lung Cancer
7%
Primaquine
7%
Vancomycin
7%
CYP3A4
6%
Ethinylestradiol
6%
Transdermal
6%
Placebo
6%
Model Selection
6%
Moderate Hepatic Impairment
5%
Iontophoresis
5%